Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-22

Clinical Trial Update: An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating amatuximab (MORAb-009) for malignant pleural mesothelioma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • amatuximab (amatuximab)

Snippet

Sponsor: Morphotek | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-22